We have identified five mutations in antithrombin by direct sequencing
of exons amplified using polymerase chain reaction. Four of these mut
ations are associated with thrombosis, three cause type I antithrombin
deficiency and one has features of a type II deficiency, The fifth va
riant appears to have no functional consequences. The type I mutations
are in exon 2, exon 3b and exon 4. The first of these is a nonsense m
utation causing substitution of a Tyr --> stop at position -16 within
the secretion signal sequence. The second is a missense mutation resul
ting in the substitution Cys --> Ser at position 247. This disrupts th
e disulphide bond with Cys 430 leaving a free cysteine residue and the
C-terminus unconstrained. The third type I mutation is an in-frame de
letion resulting in the loss of Ile 186. This is a highly conserved re
sidue in the serpin superfamily and will predictably result in the dis
ruption of the F-helix, The fourth mutation, in exon 3a, results in th
e substitution of Ser 162 by Asn. This residue is sited in the E-helix
and the replacement of the buried side chain of serine by the larger
asparagine side chain will predictably cause structural perturbation.
The last example, Val 415 --> Asp, was an incidental finding as a foll
ow up investigation of a nephrotic patient. Although one other member
of the family also had the mutation there was no linked history of thr
ombotic disease.